Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge Sells 15,000 Shares

Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $105.02, for a total transaction of $1,575,300.00. Following the transaction, the president now directly owns 1,486,241 shares of the company’s stock, valued at approximately $156,085,029.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Stephen Hoge also recently made the following trade(s):

• On Thursday, February 29th, Stephen Hoge sold 2,388 shares of Moderna stock. The shares were sold at an average price of $94.57, for a total transaction of $225,833.16.

Moderna Stock Down 0.3 %

NASDAQ:MRNA opened at $103.44 on Thursday. The firm’s 50-day moving average price is $100.10 and its 200-day moving average price is $93.52. The company has a market capitalization of $39.61 billion, a PE ratio of -8.34 and a beta of 1.62. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.42 and a quick ratio of 3.36. Moderna, Inc. has a 1-year low of $62.55 and a 1-year high of $144.93.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.78) by $1.33. The firm had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.53 billion. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The company’s revenue was down 44.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.61 EPS. On average, equities analysts predict that Moderna, Inc. will post -7.51 EPS for the current fiscal year.

Institutional Trading of Moderna

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its position in shares of Moderna by 22.6% in the 4th quarter. Vanguard Group Inc. now owns 33,907,072 shares of the company’s stock worth $3,372,058,000 after buying an additional 6,248,623 shares during the period. Wellington Management Group LLP grew its position in Moderna by 28.8% during the 4th quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock valued at $718,584,000 after purchasing an additional 1,614,460 shares during the last quarter. Geode Capital Management LLC grew its position in Moderna by 1.3% during the 1st quarter. Geode Capital Management LLC now owns 6,244,957 shares of the company’s stock valued at $957,063,000 after purchasing an additional 77,265 shares during the last quarter. Morgan Stanley grew its position in Moderna by 19.1% during the 4th quarter. Morgan Stanley now owns 4,187,353 shares of the company’s stock valued at $752,133,000 after purchasing an additional 670,284 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in Moderna by 77.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,876,147 shares of the company’s stock valued at $400,367,000 after purchasing an additional 1,690,341 shares during the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. HSBC restated a “reduce” rating and issued a $86.00 price objective (up from $75.00) on shares of Moderna in a report on Monday, February 26th. Oppenheimer upgraded shares of Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price target for the company in a report on Tuesday, January 2nd. Canaccord Genuity Group upped their price target on shares of Moderna from $82.00 to $91.00 and gave the company a “hold” rating in a report on Friday, February 23rd. Jefferies Financial Group reiterated a “buy” rating and set a $125.00 price target on shares of Moderna in a report on Tuesday, April 9th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a report on Thursday, April 11th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $126.49.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.